$Vir Biotechnology, Inc.(VIR)$

Glaxo Antibody Treatment Works on Omicron Mutations in Study

7 December 2021

GlaxoSmithKline Plc said research shows its Covid-19 antibody treatment is effective against the full combination of mutations in the new omicron variant.

Tests done in-vitro against a pseudo-virus that recreates a synthesized version of omicron showed that sotrovimab, Glaxo’s antibody treatment, stands up to all mutations in the spike protein of the omicron variant and not just the key mutations, the drugmaker said in a statement Tuesday. The tests included all 37 mutations identified to-date in the spike protein.

Does this mean VIR will spike now?

免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。

举报

评论3

  • 推荐
  • 最新
  • FabianGracie
    ·2021-12-08
    this family of COVIDs is very clever, just as each generation of venom becomes more destructive.🤣🤣
    回复
    举报
  • Tracccy
    ·2021-12-08
    I believe the vaccine of the future can defeat this virus completely! I don't like wearing masks!🤧
    回复
    举报
  • JulianAlerander
    ·2021-12-08
    I can only say that today's medical companies are prepared and not as unprepared as they used to be
    回复
    举报